CONMED Corporation Announces Fourth Quarter and Fiscal Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
CONMED (CNMD) PT Raised to $71 at Needham & Company
February 1, 2018 6:22 AM ESTNeedham & Company raised its price target on CONMED (NASDAQ: CNMD) to $71.00 (from $58.00) while maintaining a Buy rating.
Analyst Mike Matson commented, "CNMD's 4Q17 revenue and EPS beat consensus and management guided to above-consensus 2018 revenue and EPS. Its revenue growth improved to... More
